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Abstract
Background: Molecular mechanisms of intrinsic or acquired radioresistance serve as critical barrier for curative
therapy of head and neck squamous cell carcinoma (HNSCC) and remain a major obstacle for progression-free
and disease-specific survival.
Methods: HNSCC cell lines were treated with a protocol of fractionated irradiation (IR, 4× 2Gy) alone or in combination
with antagonists of estrogen receptor signaling and viability was determined by a colony-forming assay (CFA). Expression
of submaxillary gland androgen-regulated protein 3A (SMR3A) and estrogen receptor 2 (ESR2) were assessed in tumor
cells in vitro by RQ-PCR, Western blot analysis and immunofluorescence staining, and by immunohistochemical staining
of tissue microarrays containing tumor sections from patients with oropharyngeal squamous cell carcinoma
(OPSCC), which were treated by definitive or adjuvant radiotherapy. Subgroups with distinct SMR3A and ESR2
expression patterns were correlated with clinical parameters and survival outcome including multivariable analysis.
Results: Fractionated irradiation (IR) revealed an accumulation of tumor cells with prominent SMR3A expression, which
was accompanied by an up-regulation of the estrogen receptor 2 (ESR2). ESR2-dependent regulation of SMR3A
was supported by induced expression after stimulation with estradiol (E2), which was impaired by co-treatment
with 4-Hydroxytamoxifen (TAM) or Fulvestrant, respectively. Both drugs significantly sensitized FaDu cells to fractionated IR
as determined by a CFA and accelerated apoptosis. These data suggest a critical role of ESR2 in radioresistance and that
SMR3A might serve as a surrogate marker for active ESR2 signaling. In line with this assumption, ESR2-positive
oropharyngeal squamous cell carcinoma (OPSCC) with high SMR3A expression had an unfavorable progression-
free and disease-specific survival as compared to those tumors with low SMR3A expression.
Conclusions: In summary, our findings provide compelling experimental evidence that HNSCC with SMR3A
and ESR2 co-expression have a higher risk for treatment failure and these patients might benefit from clinically
well-established drugs targeting estrogen receptor signaling.
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Background
Head and neck cancer is one of the most prevalent human
malignancies with an annual incidence of approximately
600,000 new cases worldwide [1]. The majority are head
and neck squamous cell carcinoma (HNSCC) originating
from the mucosal epithelia of the upper aerodigestive
tract. HNSCC is a rather heterogeneous disease and des-
pite aggressive, multimodal treatment of locally advanced
tumors a significant proportion of patients develop disease
recurrence due to either local or distant failure [2]. Given
that many patients with a recurrent HNSCC are no longer
amenable to curative therapy, the ensuing morbidity is
high and survival is dismal [3]. Consequently, appropriate
treatment of HNSCC patients remains a major challenge
and there is an urgent demand in a better understanding
of molecular principles underlying treatment failure.
In the past, we applied global gene expression profiling
on matched samples of primary and recurrent tumors of
an orthotopic squamous cell carcinoma model in mice
to identify differentially expressed genes [4]. One candi-
date gene with an increased transcript level in recurrent
as compared to primary tumors encoded for the mouse
homologue of human submaxillary gland androgen-
regulated protein 3A (SMR3A), which belongs to the
opiorphin gene family [5]. More recently, SMR3A
expression was detected in a subgroup of patients with pri-
mary oropharyngeal squamous cell carcinoma (OPSCC)
and served as an independent risk factor for unfavorable
prognosis [6]. However, the regulation of SMR3A and its
putative mode of action in the pathogenesis of HNSCC or
in response to treatment have not been addressed, so far.
In the current study, we demonstrate prominent SMR3A
expression in tumor cells upon fractionated irradiation (IR)
and provide experimental evidence that induced SMR3A
expression serves as a surrogate maker for active estrogen
receptor 2 (ESR2) signaling in radioresistant tumor cells.
Methods
Cell culture and stable clones
Human cell lines (FaDu and Cal27) were purchased from
ATCC (http://www.lgcstandards-atcc.org/) and were main-
tained in Dulbecco’s Modified Eagle’s Medium (Sigma-
Aldrich, Germany) supplemented with 10% fetal
bovine serum (Invitrogen, Germany), 2 mM L-Glu-
tamine (Invitrogen, Germany) and 50 μg/ml Penicillin-
Streptomycin (Invitrogen, Germany) in a humidified
atmosphere of 6% CO2 at 37 °C. Authentication of both cell
lines was confirmed by the Multiplex Human Cell Line
Authentication Test (Multiplexion, Germany, latest update
August 11th, 2016). To generate single cell clones, FaDu
cells were transfected with either pcDNA3.1 (Invitrogen,
USA) or a plasmid encoding a Myc-DDK-tagged ORF of
Homo sapiens SMR3A (Origene, USA) using FuGene HD
Transfection Reagent (Promega, Germany) according to the
manufacturer’s instruction. Following selection with 0.5–
0.8 mg/ml G418 (Calbiochem Merck, Germany) for two
weeks, single clones were isolated and ectopic SMR3A-
Myc/DDK expression was confirmed on transcript and
protein level. Two independent mock controls and FaDu-
SMR3A clones were selected for further analysis. Parental
FaDu and Cal27 cells were treated with the indicated con-
centrations of estradiol (E2) or 4-Hydroxytamoxifen (TAM)
dissolved in ethanol (EtOH) or Fulvestrant dissolved in
DMSO. All compounds were purchased from Sigma-
Aldrich, Germany.
RQ-PCR analysis
RNA extraction, cDNA synthesis and real-time quanti-
tative polymerase chain reaction (RQ-PCR) were done
as described previously [7]. Primer sequences were
selected using Primer-Blast (http://www.ncbi.nlm.nih.
gov/tools/primer-blast) and are listed in Additional file 1.
To quantify relative SMR3A transcript levels by RQ-PCR
analysis cDNA samples were used undiluted. The cycle of
threshold (CT) of the gene of interest was standardized to
the CT value of the reference gene (LMNB1) using the
ΔΔCT method.
Western blot analysis and immunofluorescence staining
Western blot analysis was performed with whole cell lysates
as described previously [8]. Membranes were incubated in
enhanced chemiluminiscence solution (Thermo Scientific,
Germany) and developed with the ImageQuant LAS500
system (GE Healthcare, Germany). Immunofluorescence
staining was done as described elsewhere [7], and pictures
were taken with the Fluorescence Microscope BX50F,
Olympus XC30 Camera and cellSens Entry imaging soft-
ware (Olympus, Germany). Antibodies and dilutions that
were used for Western blot analysis and immunofluores-
cence staining are listed in Additional file 2.
BrdU-incorporation assay
20–30,000 cells per well were seeded on glass coverslips in
12-well plates. 48 h after seeding, cells were treated for 2 h
with BrdU according to the manufacture’s instruction (BD
Pharmingen, Germany). Staining was done as described
previously [7, 8] and relative amount of proliferative cells
was calculated as the ratio of BrdU-positive versus total
cell counts.
Migration assay
Cell migration assays were performed using ibidi Culture
Inserts (Ibidi, Germany) according to the instruction of
the manufacturer. After removal of the inserts, pictures
were taken at the indicated time points using the
Keyence BZ-9000 microscope system to calculate the
relative gap closure over time.
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Colony-formation assay (CFA)
To determine the clonal expansion of tumor cells upon
fractionated irradiation, 100, 300 and 1,000 cells were
seeded per well in 6-well plates and irradiated on four con-
secutive days with a daily dose of 2 gray (Gy) using X-RAD
320 (Precision X-Ray, North Branford, CT USA) or kept
untreated as controls. Half of the cells were treated
daily with 1 μM 4-Hydroxytamoxifen (TAM, Sigma-
Adrich, Germany) or every second day with 30 nM Ful-
vestrant (Sigma-Adrich, Germany). After 10–14 days in
culture, clones were stained with crystal violet and total
amount of colonies was quantified as described in [9].
The survival fraction was computed according to [10].
Patient samples and immunohistochemistry
The retrospective study cohort, generation of tissue
microarrays, immunohistochemical staining and as-
sessment of the immunoreactivity score for SMR3A
was described before [6]. Paraffin-embedded tissue
specimens were provided by the tissue bank of the National
Center for Tumor Disease (Institute of Pathology,
University Hospital Heidelberg) after approval by the
local institutional review board (ethic votes: 176/2002
and 206/2005). The study was performed according to
the ethical standards of the Declaration of Helsinki.
For all tumor samples, clinical and follow-up data were
available from the Department of Otolaryngology, Head
and Neck Surgery at the University Hospital Heidelberg.
Immunohistochemical staining for ESR2 was done using
the 3, 3’-diaminobenzidine (DAB) peroxidase substrate kit
(Perkin Elmer, Germany) according to the manufacturer’s
instruction and the assessment of the immunoreactivity
score for ESR2 was according to the procedure described
before [6]. Clinical and histopathological features of
samples for which informative values for SMR3A and
ESR2 were available and which were included in the final
analysis are listed in Additional file 3.
Statistical analysis
Statistical analysis was done using SPSS (version 21) and
GraphPad software (http://www.graphpad.com). Differ-
ences between patient subgroups were assessed using Chi
square test. Disease-specific survival (DSS) was calculated
as the time from the date of primary tumor diagnosis to the
date of cancer-related death within the follow-up interval
(events). Survival times of patients, who were alive or were
dead due to causes other than cancer were censored.
Progression-free survival (PFS) was calculated from the
date of primary tumor diagnosis to the date of the first local
recurrence, lymph node or distant metastasis, second pri-
mary carcinoma, or date of cancer-related death within the
follow-up period (events). Patients without progression (no
event) or cancer-unrelated death were censored. The
method of Kaplan–Meier was used to estimate survival
distributions and differences between subgroups were
determined by log-rank tests. To adjust for possible con-
founders, multivariable Cox proportional hazard regression
models were fitted. Models included the covariates gender,
age, clinical staging, alcohol and tobacco consumption,
HPV status and therapy. Based on availability of complete
clinical data sets, 66 cases were included for the analysis of
subgroups with ESRhighSMR3Alow versus ESRhighSMR3A-
high staining patterns and 103 cases were included for the
analysis of subgroups with ESRhighSMR3Alow versus all
other staining patterns.
In all statistical tests, a p-value of 0.05 or below was
considered as statistically significant.
Results
Establishment and analysis of a HNSCC cell line with
ectopic SMR3A expression
SMR3A expression was assessed by RQ-PCR analysis
with cDNA from human HNSCC cell lines. Transcript
levels were close to the detection limit in all cell lines
tested, indicating no or a rather low SMR3A expression
under normal growth conditions (data not shown). FaDu
cells were selected to generate stable clones (FaDu-
SMR3A) with ectopic SMR3A expression in order to
address its impact on tumor-relevant processes in vitro.
Ectopic expression in FaDu-SMR3A clones was confirmed
on transcript and protein levels (Additional file 4a-c). How-
ever, we did not observe any significant difference in
tumor cell proliferation or migration between FaDu-
SMR3A clones and mock controls (Additional file 4d-e).
In summary, these data suggested that SMR3A has no
major impact on tumor cell physiology under normal
growth conditions but raised the attractive question,
whether it serves as a marker for a distinct subpopula-
tion of tumor cells with higher resistance against well-
established treatment options.
SMR3A expression in HNSCC cells upon fractionated
irradiation
To support this assumption, FaDu cells were treated with
fractionated irradiation (IR, 4× 2Gy), which revealed a
prominent SMR3A staining in all vital cells after treatment
as determined by IF analysis (Fig. 1a-b). It is worth noting
that we observed a gradual increase in the relative amount
of positive cells with increasing cycles of fractionated IR
(Additional file 5a and data not shown). An induction after
fractionated IR was also detected in Cal27 cells, though the
staining was more heterogeneous and not all vital cells were
SMR3A-positive (Fig. 1b). In both cell lines induced
SMR3A expression after fractionated IR was confirmed on
transcript level (Fig. 1c). However, the induction as
compared to control-treated cells was highly significant
for FaDu cells, while in Cal27 cells a clear trend was
found without reaching statistical significance.
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SMR3A is a downstream target of ESR2 signaling
In the past, several studies in rodents provided experi-
mental evidence for the regulation of opiorphin family
members by steroid hormones [11–13]. To assess
whether hormone signaling also contributes to SMR3A
regulation during fractionated IR, expression of the
androgen receptor (AR) as well as estrogen receptor 1
and 2 (ESR1 and ESR2) was analyzed in FaDu and
Cal27 cells on transcript and protein levels. No AR and
ESR1 expression was detected under normal growth
conditions and only few cells exhibited a minor staining
for ESR1 after fractionated IR (Fig. 2a, Additional file 5b
and data not shown). In contrast, ESR2 was expressed in
both cell lines and was strongly induced after fractionated
IR (Fig. 2a-c). Again, the amount of ESR2-positive cells
was more heterogeneous in Cal27 as compared to
FaDu cells and accumulated with increasing cycles of
fractionated IR (Additional file 5a), suggesting regula-
tion of SMR3A expression by ESR2-dependent signal-
ing. In line with this assumption, stimulation of FaDu
cells with estradiol (E2) revealed a significant and
concentration dependent increase of SMR3A transcript
levels (Fig. 2d), which was impaired by co-treatment with
4-Hydroxytamoxifen (TAM) or pre-treatment with
Fulvestrant (Fig. 2e-f). In summary, these data sug-
gested that SMR3A expression serves as a potential
surrogate marker for active ESR2 signaling in a
subpopulation of radioresistant tumor cells, raising the
question, whether pharmacological interference sensitizes
these cells to fractionated IR.
Inhibition of ESR2 signaling in combination with
fractionated IR
As a proof of concept, fractionated IR was applied to
FaDu cells with or without administration of TAM or
Fulvestrant, respectively (Additional file 6). Fulvestrant
inhibited irradiation-induced ESR2 expression as deter-
mined by IF staining and Western blot analysis (Fig. 3a-b),
and augmented apoptosis, which was monitored by
elevated caspase three and PARP cleavage (Fig. 3c). An in-
crease in apoptosis was also detected for administration of
TAM in combination with fractionated IR (Fig. 3c). A
higher radiosensitivity of FaDu cells by inhibition of ESR2
signaling was further confirmed in a colony-forming assay
after fractionated IR alone or in combination with
Fulvestrant or TAM treatment (Fig. 3d-e). In line with
the less efficient induction of ESR2 and SMR3A, Cal27
exhibited a reduced relative survival fraction after frac-
tionated irradiation as compared to FaDu cells, sug-
gesting a positive correlation between ESR2 induction
and radioresistance. Furthermore, in Cal27 cells only
administration of TAM but not Fulvestrant revealed a
significant decrease in the relative survival fraction
upon fractionated IR.
Fig. 1 SMR3A expression in HNSCC cell lines after fractionated IR. a Schematic summary of the treatment protocol for fractionated IR. Prominent SMR3A
expression in FaDu and Cal27 cells after fractionated IR (4× 2Gy) was demonstrated by immunofluorescence staining on protein level b (red signal) and
by RQ-PCR on transcript level (c) Cell nuclei were counterstained with Hoechst H33342 (blue signal). Scale bars = 20 μm. Bars represent mean values ±
SEM of two independent experiments measured in triplicates with quantification of LMNB1 transcript levels as reference gene. *** p ≤0.0005
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Co-expression of ESR2 and SMR3A in tumor samples and
correlation with clinical features
So far, experimental data support a model in which ESR2
and SMR3A co-expression after fractionated IR is a charac-
teristic feature for a subpopulation of treatment resistant
tumor cells. In line with this model the detection of
SMR3A expression in tumor cells prior to therapy might
serve as a surrogate marker for active ESR2 signaling
during malignant progression and the presence of tumor
cells with intrinsic radioresistance. To address the clinical
relevance of our in vitro findings, we assessed ESR2 expres-
sion by IHC staining on tissue microarrays containing
tumor specimens of OPSCC patients, which were treated
with either definitive or post-surgical radiotherapy with or
without adjuvant chemotherapy. Data on SMR3A staining
on serial sections were already available from a previous
retrospective study [6]. Evaluable staining patterns for both
proteins were obtained for n = 109 OPSCC patients (Fig. 4a),
and clinical features of the study cohort are summarized in
Additional file 3. Positive staining for ESR2 (ESR2pos) in
tumor cells was detected in 65.1% of tumors and a high
staining pattern correlated significantly with a higher
SMR3A immunoreactivity score as compared to samples
without detectable ESR2 staining (Fig. 4b, p = 0.044). We
did not observe a statistically significant correlation
between ESR2neg and ESR2pos subgroups and patient
characteristics tested, except for age, T status and
tobacco consumption. Significant associations were due to
an older age, smaller tumor size and an enrichment of
never/former smokers in the subgroup with ESR2pos
staining (Additional file 7). Concerning progression-free
(PFS) and disease-specific survival (DSS), univariate
analysis revealed an unfavorable clinical outcome in the
absence of ESR2 staining as compared to ESR2pos tumors
(Fig. 4c-d). However, patients with ESR2pos tumors had a
significantly shorter PFS and DSS in the presence of high
SMR3A expression, similar to the ESR2neg subgroup, while
ESR2posSMR3Alow tumors exhibited the most favorable
clinical outcome (Fig. 4c-d, Additional file 8). Multivariable
Cox proportional hazard regression models adjusted for the
covariates gender, age, clinical staging, alcohol and tobacco
consumption, HPV status and therapy supported a favor-
able PFS and DSS of the subgroup with an ESR2highSM-
R3Alow staining as compared to either ESR2highSMR3Ahigh
or all other staining patterns (Additional file 9).
Discussion
Radiotherapy remains a mainstay of local treatment for
HNSCC and improvements in intensity-modulated tech-
niques and new protocols of altered fractionation have con-
tributed to reduced mortality and long-term morbidity with
a strong impact on the quality of life [14]. However,
Fig. 2 Regulation of SMR3A expression by ESR2 signaling. Western blot analysis revealed basal expression of ESR2 but not ESR1 protein in tumor
cell lines (a) which was induced by fractionated IR as demonstrated by immunofluorescence staining b (red signal). Cell nuclei were counterstained
with Hoechst H33342 (blue signal). Scale bars = 20 μm. Induced ESR2 protein expression after fractionated IR was confirmed in FaDu cells by Western
blot analysis (c). Detection of β-Actin served as a control for protein quality and quantity. RQ-PCR revealed concentration dependent induction of
relative SMR3A transcript levels by E2 in FaDu cells (d) which was impaired by administration of 1 μM TAM (e) or 10 nM Fulvestrant (f) respectively. Bars
represent mean values ± SEM of at least two independent experiments measured in triplicates with quantification of LMNB1 transcript levels as
reference gene. * p ≤ 0.05, *** p ≤ 0.0005
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intrinsic and acquired resistance remains a major obstacle
and serves as a critical barrier for curative treatment of can-
cer patients, including HNSCC [15]. Unraveling molecular
principles of radioresistance and subsequent clonal expan-
sion of vital tumor cells is a crucial task to establish prog-
nostic biomarkers for HNSCC patients with a higher risk
for treatment failure and to identify new drug targets for
more efficient and less toxic therapy.
In this study, we unraveled prominent SMR3A expres-
sion in vital tumor cells upon fractionated IR. Although
ectopic SMR3A expression had no significant impact on
tumor-relevant processes under normal growth condi-
tions in vitro, presented data provide compelling experi-
mental evidence that it might serve as a surrogate
marker for a subpopulation of resistant cells as a puta-
tive source for tumor relapse after radiotherapy. In line
with this assumption, a previous retrospective study un-
raveled high SMR3A expression as a risk factor for
unfavorable progression-free and overall survival in a
cohort of OPSCC patients [6].
Studies in rodents revealed a positive regulation of
opiorphin family members by hormone signaling [11–13],
and our findings indicate that ESR2 signaling not only in-
duces SMR3A expression but also plays a critical role in
resistance to treatment. This assumption is further sup-
ported by recent reports demonstrating that the presence
of ESR2 modulates response to several therapeutic agents
in breast and lung cancer cells [16–18]. So far, only a lim-
ited number of studies focused on estrogen receptor sig-
naling in the pathogenesis or prognosis of HNSCC.
Already in 1988, Somers and colleagues demonstrated that
estrogen treatment potentiated growth of laryngeal tu-
mors in a xenograft model in vivo [19]. More recently, a
functional crosstalk between estrogen and EGF receptor
signaling was reported, which might contribute to neo-
plastic transformation and disease progression of HNSCC
[20]. Conflicting data were published with regard to the
expression pattern of ESR1 and ESR2 in HNSCC and their
correlation with clinical outcome [20–23]. However, in
line with our data two studies found a frequent expression
Fig. 3 Impact of TAM or Fulvestrant treatment on fractionated IR of FaDu cells. a Representative pictures of an immunofluorescence staining of
control (DMSO) and 10 nM Fulvestrant-treated FaDu cells with or without fractionated IR (4× 2Gy) demonstrate reduced basal and impaired
induction of ESR2 protein levels (green signal) by Fulvestrant, which is confirmed by Western blot analysis (b) Cell nuclei were counterstained with
Hoechst H33342 (blue signal). c Western blot analysis indicates accelerated apoptosis by the combination of fractionated IR with 1 μM TAM or
10 nM Fulvestrant, respectively, as determined by increased levels of cleaved caspase three and PARP (indicated by the arrowhead). Detection of
β-Actin served as a control for protein quality and quantity. d-e Graphs represent the relative survival fraction of FaDu and Cal27 cells in a colony-
forming assay after fractionated IR (4× 2Gy) and either 30 nM Fulvestrant or 1 μM TAM administration, respectively. Control-treated cells are set to
one and bars represent mean values ± SEM of at least three independent experiments. * p≤ 0.05
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of ESR2 but not ESR1 in HNSCC cell lines and tumor tis-
sues [21, 22], suggesting a more prominent role of ESR2-
related signaling.
In contrast to ESR1, ESR2 is usually described as a tumor
suppressor in estrogen-sensitive malignancies [24]. How-
ever, we detected a positive staining for ESR2 expression as
a common event in OPSCC, while ESR1-positive tumor
cells were a rather rare event (data not shown). In line with
our hypothesis that SMR3A serves as a surrogate marker
for active ESR2 signaling and predicts treatment resistance,
the combined expression of both proteins was associ-
ated with an unfavorable clinical outcome concerning
progression-free and disease-specific survival after
definitive or adjuvant radiotherapy. Although multi-
variable Cox proportional hazard regression models
supported the assumption that ESR2 and SMR3A
staining patterns are associated with clinical outcome,
our retrospective study is limited by the low amount of
patients for distinct subgroups. A major challenge for
the future will be the analysis of ESR2 and SMR3A but
also other downstream targets in larger cohort studies,
including specimens from HNSCC of other locations.
It is worth noting that OPSCC without detectable ESR2
expression were also correlated with a poor survival, indi-
cating that the prognostic value of ESR2 expression is
context dependent and that ESR2-negative and positive
tumors represent two distinct subgroups of HNSCC which
most likely differ in their cellular and molecular traits. In
the past, the prognostic value of ESR2 expression in other
human malignancies, including breast, ovarian, bladder,
prostate and lung cancer, was controversially discussed fur-
ther supporting a strong context dependency [17, 25–33].
Nevertheless, a negative staining in a tumor biopsy taken at
the time point of diagnosis or during primary surgery does
not exclude induction and/or expansion of ESR2-positive
tumor cells during fractionated radiotherapy. Innovative
tools, such as irradiation of ex vivo cultures derived from
vital tumor tissue [34, 35], might be appropriate pre-clinical
models to address this issue and could help to select indi-
vidual patients for new treatment options.
Conclusions
In summary, our data suggest that HNSC’C with a com-
bined ESR2 and SMR3A expression are at a higher risk
Fig. 4 SMR3A and ESR2 expression in HNSCC patients. a Representative pictures of immunohistochemical staining (brown signal) of serial tumor
sections with anti-ESR2 (left row) or anti-SMR3A antibodies (right row). Haematoxyline counterstaining (blue staining) demonstrates the
tissue architecture. Scale bars = 500 μM. b Boxblot depicts the SMR3A immunoreactivity score as mean value and 5th/95th percentile for
individual tumors with low, moderate or high ESR2 staining pattern. c-d Kaplan-Meier graphs show differences in disease-specific (DSS)
and progression-free survival (PFS) between subgroups without detectable ESR2 staining (ESR2neg, blue line) and ESR2-positive tumors
with low (green line) or high SMR3A expression (red line)
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for treatment failure upon radiotherapy, but might benefit
from treatment with TAM or Fulvestrant, two clinically
well-established inhibitors targeting estrogen receptor
signaling [36]. Indeed, both drugs significantly sensitized
tumor cells to fractionated IR and an accelerated
sensitivity to chemotherapy after administration of
Fulvestrant was demonstrated recently for of estrogen
receptor positive breast and lung cancer cells [37, 38].
However, additional cohort studies and preclinical
models are required to confirm the clinical relevance
of our findings and as a proof-of-concept for the efficacy
of TAM or Fulvestrant in combination with radiotherapy
for HNSCC patients.
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